newsfilter
← Latest News
GlobeNewswire·

Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025

CVKD
  • Cadrenal Therapeutics, Inc. (NASDAQ: CVKD) will participate in the Lytham Partners Fall 2025 Investor Conference on Tuesday, September 30, 2025.
  • The event will be held virtually, featuring a webcast presentation at 3:30 p.m. ET.
  • The webcast can be accessed at https://lythampartners.com/fall2025/ or https://app.webinar.net/QG1g6kJWEM0, with a replay available post-event.
  • Management will host virtual one-on-one meetings throughout the conference; arrangements can be made by contacting Lytham Partners at 1x1@lythampartners.com or registering at https://lythampartners.com/fall2025invreg/.
  • Cadrenal is developing tecarfarin, a novel oral Vitamin K antagonist anticoagulant designed to address gaps in current therapy.
  • Tecarfarin is a reversible blood thinner intended to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation.
  • The company aims to reduce clinical complexities associated with Vitamin K antagonists where direct-acting oral anticoagulants (DOACs) are inadequate.
  • Tecarfarin received Orphan Drug Designation (ODD) and fast-track designation for preventing systemic thromboembolism in patients with end-stage kidney disease and atrial fibrillation.
  • The company also received ODD for preventing thromboembolism in patients with implanted mechanical circulatory support devices, including Left Ventricular Assist Devices (LVADs).
  • Matthew Szot serves as CFO for Cadrenal Therapeutics, while Robert Blum is the Managing Partner at Lytham Partners.